Oyster Point Pharma attains primary endpoint in MYSTIC trial
Category: #health  By Pankaj Singh  Date: 2020-01-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Oyster Point Pharma attains primary endpoint in MYSTIC trial

A clinical-stage biopharmaceutical company, Oyster Point Pharma, Inc. recently announced positive results from its Phase 2 MYSTIC clinical study for Dry Eye Disease.

For the record, Oyster Point Pharma is focused upon discovering, developing, and commercializing novel pharmaceutical therapies to treat ocular surface diseases.

Dr. Preeya Gupta, Associate Professor, Ophthalmology at Duke University Eye Center and advisory board member at Oyster Point Pharma was quoted saying that the findings from the MYSTIC study validate the efficient mechanism of action of OC-O1 and its ability to promote natural tear production via the trigeminal parasympathetic pathway. Preeya Gupta added saying that there is a considerable need for a treatment option that can be delivered regularly through a novel route of administration that can stimulate natural tear film in patients along with addressing the underlying disease process.

The study indicated that OC-01 nasal spray was well-tolerated at the 2 doses tested. 24% of the subjects reported TEAE (treatment-emergent adverse event); which is 10 out of 41 in each nasal spray dose group. There were no serious adverse events related to study drug administration and no incidence of serious treatment-emergent adverse events (AE). The most common AE in the nasal spray groups were sneezing, headache, and blurry vision. All these events were minor in the nasal spray groups and were sorted by the next visit.

Dr. Jeffrey Nau, Chief Executive Officer of Oyster Point Pharma remarked that the company is exhilarated to further validate OC-01 nasal sprays’ ability to stimulate an increase in tear film production, which is sustained over the course of twice daily dosing for 84 days in patients with Dry Eye Disease from the MYSTIC study. Dr. Nau further added saying that they are looking forward to discussing top-line data from the Phase 3 study (ONSET 2) in Dry Eye Disease by mid-2020.

Source Credit: https://investors.oysterpointrx.com/news-releases/news-release-details/oyster-point-pharmas-oc-01-nasal-spray-meets-primary-endpoint

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Adverum Biotechnologies announces new data from OPTIC Phase 1 trial
Adverum Biotechnologies announces new data from OPTIC Phase 1 trial
By Pankaj Singh

Adverum Biotechnologies, a California based biotech company, has reportedly announced new clinical data from the OPTIC Phase 1 with dose ranging clinical stage trial of gene therapy intravitreal injection namely ADVM-022. The OPTIC trial has enrolle...

Premier to buy two Greater New York Hospital Association subsidiaries
Premier to buy two Greater New York Hospital Association subsidiaries
By Pankaj Singh

Premier Inc., a renowned healthcare improvement company, has reportedly announced that it has entered a definitive agreement to purchase certain liabilities and all the assets of Nexera, Inc. and Acurity, Inc., two wholly owned indirect subsidiaries ...

Mitsubishi creates new technology to control in-building mobile robots
Mitsubishi creates new technology to control in-building mobile robots
By Pankaj Singh

Mitsubishi Electric Corporation has recently announced its technological development to control in-building mobile robots, by using building dynamic maps. This new 3D building map will show the status of mobilities within the building, including thei...